Clinical Trial Detail

NCT ID NCT03157089
Title Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung (LUX-Lung IO)
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Boehringer Ingelheim
Indications

lung squamous cell carcinoma

Therapies

Afatinib + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.